{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:26:21Z","timestamp":1793298381090,"version":"4.5.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270767"],"award-info":[{"award-number":["82270767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Hematopoietic stem cell transplant (HSCT) is a well-established procedure for malignant and nonmalignant conditions. Despite its therapeutic benefits, kidney disease remains a common complication that significantly affects patient outcomes. Kidney injury post-HSCT manifests as acute kidney injury and chronic kidney disease, with multifactorial causes such as conditioning regimens, nephrotoxic drugs, graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (TA-TMA). Accurate diagnosis often requires a kidney biopsy due to overlapping risk factors and complex clinical presentations. This review summarizes current diagnostic and therapeutic standards, highlights advance in biomarkers and pathophysiology, and discusses targeted therapies such as rituximab for GVHD-related glomerulopathies and eculizumab for TA-TMA. Supportive care, immunomodulation, and early intervention remain critical. For patients progressing to end stage renal disease, renal replacement therapy and kidney transplantation post-HSCT offer viable long-term options. Despite these advances, challenges persist, including the need for noninvasive diagnostic tools and standardized management protocols. Future research into pathophysiology, biomarkers, and targeted therapies holds promise for improving outcomes in this field.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf139","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T10:06:00Z","timestamp":1752746760000},"page":"2268-2279","source":"Crossref","is-referenced-by-count":3,"title":["Kidney disease after hematopoietic stem cell transplant\u2014treatment standard"],"prefix":"10.1093","volume":"40","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Fu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-9426","authenticated-orcid":false,"given":"Xianghua","family":"Huang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University , Nanjing ,","place":["China"]},{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025112604020861900_bib1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Haematol"},{"key":"2025112604020861900_bib2","doi-asserted-by":"publisher","first-page":"455.e451","DOI":"10.1016\/j.jtct.2023.03.029","article-title":"Clinical features of acute kidney injury in the early post-transplantation period following reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Vergara-Cadavid","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025112604020861900_bib3","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal complications of hematopoietic-cell transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N Engl J Med"},{"key":"2025112604020861900_bib4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2215\/CJN.01700407","article-title":"Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature","volume":"2","author":"Chang","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112604020861900_bib5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jtct.2021.03.012","article-title":"Guidelines for the prevention and management of graft-versus-host disease after cord blood transplantation","volume":"27","author":"Ponce","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025112604020861900_bib6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2025112604020861900_bib7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"key":"2025112604020861900_bib8","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"2025112604020861900_bib9","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112604020861900_bib10","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025112604020861900_bib11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-017-0708-2","article-title":"Daclizumab: a review in relapsing multiple sclerosis","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"2025112604020861900_bib12","doi-asserted-by":"publisher","first-page":"749266","DOI":"10.3389\/fimmu.2021.749266","article-title":"Meta-analysis of interleukin-2 receptor antagonists as the treatment for steroid-refractory acute graft-versus-host disease","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"2025112604020861900_bib13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.bbmt.2014.05.022","article-title":"Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes","volume":"20","author":"Chang","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112604020861900_bib14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood.V100.1.334","article-title":"Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide","volume":"100","author":"Eissner","year":"2002","journal-title":"Blood"},{"key":"2025112604020861900_bib15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025112604020861900_bib16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41409-023-02161-7","article-title":"Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from japanese aHUS post-marketing surveillance","volume":"59","author":"Ito","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2025112604020861900_bib17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"2025112604020861900_bib18","doi-asserted-by":"publisher","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of Eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2025112604020861900_bib19","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"2025112604020861900_bib20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1537-2995.2012.03776.x","article-title":"Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?","volume":"53","author":"Jodele","year":"2013","journal-title":"Transfusion"},{"key":"2025112604020861900_bib21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2018.08.016","article-title":"Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: an institutional experience","volume":"25","author":"Sartain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112604020861900_bib22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/MOH.0000000000000687","article-title":"Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy","volume":"28","author":"Schoettler","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"2025112604020861900_bib23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","article-title":"Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience","volume":"59","author":"Castelli","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2025112604020861900_bib24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2025112604020861900_bib25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/trf.13437","article-title":"Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin","volume":"56","author":"Fujiwara","year":"2016","journal-title":"Transfusion"},{"key":"2025112604020861900_bib26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000545198","article-title":"Clinical manifestations and prognosis of chronic kidney disease after hematopoietic stem cell transplantation","volume":"11","author":"Zhang","year":"2025","journal-title":"Kidney Dis"},{"key":"2025112604020861900_bib27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/bmt.2013.55","article-title":"GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation","volume":"48","author":"Sakellari","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025112604020861900_bib28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1159\/000504354","article-title":"Risk factors for acute kidney injury and chronic kidney disease following allogeneic hematopoietic stem cell transplantation for hematopoietic malignancies","volume":"143","author":"Sakaguchi","year":"2020","journal-title":"Acta Haematol"},{"key":"2025112604020861900_bib29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.bbmt.2015.12.014","article-title":"Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy","volume":"22","author":"Beyar-Katz","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112604020861900_bib30","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/ndt\/gfl795","article-title":"Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects","volume":"22","author":"Terrier","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025112604020861900_bib31","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112604020861900_bib32","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/bloodadvances.2024014374","article-title":"Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis","volume":"9","author":"Pidala","year":"2025","journal-title":"Blood Adv"},{"key":"2025112604020861900_bib33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"2025112604020861900_bib34","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112604020861900_bib35","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"2025112604020861900_bib36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 Inhibition with Belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112604020861900_bib37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"key":"2025112604020861900_bib38","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025112604020861900_bib39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025112604020861900_bib40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1053\/j.ajkd.2005.01.003","article-title":"Nephrotic syndrome in patients with peripheral blood stem cell transplant","volume":"45","author":"Rao","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2025112604020861900_bib41","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s40121-023-00841-x","article-title":"Applying Rituximab during the conditioning regimen prevents Epstein-Barr Virus infection following allogeneic hematopoietic stem cell transplant in a children's cohort: a retrospective case-control study","volume":"12","author":"Ruan","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025112604020861900_bib42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7326\/0003-4819-133-4-200008150-00011","article-title":"Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease","volume":"133","author":"Ratanatharathorn","year":"2000","journal-title":"Ann Intern Med"},{"key":"2025112604020861900_bib43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.akdh.2024.02.002","article-title":"Minimal change disease","volume":"31","author":"Gomez","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"2025112604020861900_bib44","doi-asserted-by":"publisher","first-page":"e13633","DOI":"10.1111\/ctr.13633","article-title":"Amlodipine and calcineurin inhibitor-induced nephrotoxicity following allogeneic hematopoietic stem cell transplant","volume":"33","author":"Jensen","year":"2019","journal-title":"Clin Transplant"},{"key":"2025112604020861900_bib45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2018.06.013","article-title":"Emerging concepts in hematopoietic stem cell transplantation-associated renal thrombotic microangiopathy and prospects for new treatments","volume":"72","author":"Wanchoo","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2025112604020861900_bib46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1053\/j.seminhematol.2011.10.008","article-title":"Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines","volume":"49","author":"Abboud","year":"2012","journal-title":"Semin Hematol"},{"key":"2025112604020861900_bib47","doi-asserted-by":"publisher","first-page":"632263","DOI":"10.3389\/fonc.2021.632263","article-title":"Continuous renal replacement therapy: a review of use and application in pediatric hematopoietic stem cell transplant recipients","volume":"11","author":"Elbahlawan","year":"2021","journal-title":"Front Oncol"},{"key":"2025112604020861900_bib48","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1097\/TP.0000000000003477","article-title":"Long-term outcomes of sequential hematopoietic stem cell transplantation and kidney transplantation: single-center experience","volume":"105","author":"Moreira","year":"2021","journal-title":"Transplantation"},{"key":"2025112604020861900_bib49","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/ajt.12731","article-title":"Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression","volume":"14","author":"Kawai","year":"2014","journal-title":"Am J Transplant"},{"key":"2025112604020861900_bib50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajt.14970","article-title":"Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor\u2014a multicenter analysis","volume":"19","author":"Eder","year":"2019","journal-title":"Am J Transplant"},{"key":"2025112604020861900_bib51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"2025112604020861900_bib52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/ph15070845","article-title":"Complement system as a new target for hematopoietic stem cell transplantation-related thrombotic microangiopathy","volume":"15","author":"Ardissino","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2025112604020861900_bib53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12887-023-03996-1","article-title":"Pathological evaluation of renal complications in children following allogeneic hematopoietic stem cell transplantation: a retrospective cohort study","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Pediatr"},{"key":"2025112604020861900_bib54","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ckj\/sfac264","article-title":"Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation","volume":"16","author":"Yap","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025112604020861900_bib55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000529699","article-title":"Patterns of renal dysfunction and profile of kidney biopsies in hematopoietic stem cell transplant recipients","volume":"3","author":"John","year":"2023","journal-title":"Glomerular Dis"},{"key":"2025112604020861900_bib56","doi-asserted-by":"publisher","first-page":"e12418","DOI":"10.7759\/cureus.12418","article-title":"Kidney recovery from acute kidney injury after hematopoietic stem cell transplant: a systematic review and meta-analysis","volume":"13","author":"Kanduri","year":"2021","journal-title":"Cureus"},{"key":"2025112604020861900_bib57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41409-023-02136-8","article-title":"AKI treated with kidney replacement therapy in critically ill allogeneic hematopoietic stem cell transplant recipients","volume":"59","author":"Kim","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2025112604020861900_bib58","doi-asserted-by":"publisher","first-page":"282.e281","DOI":"10.1016\/j.jtct.2022.12.023","article-title":"Systematic review of signs and symptoms associated with hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"29","author":"Dandoy","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf139\/63789947\/gfaf139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/12\/2268\/63789947\/gfaf139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/12\/2268\/63789947\/gfaf139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T09:02:12Z","timestamp":1764147732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/12\/2268\/8205567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,17]]},"published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf139","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,17]]}}}